Amanda Cashen, MD

Bone Marrow Transplant Specialist, Medical Oncologist

Amanda Cashen

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Amanda Cashen, MD

Watch video on YouTube

Amanda Cashen, MD

6 mins

Amanda Cashen, MD, WashU Medicine Medical Oncologist at Siteman Cancer Center discusses the complexity of patient education around blood cancers leukemia and lymphoma.

“The best part of my job is the time I’m sitting in the room with my patient to get to know them and be able to educate them about their diagnosis and our treatment plan… I always start by getting to know the patient. It’s important for me to know who they are.”

Dr. Amanda Cashen, MD

Clinical Expertise

  • As a member of our leukemia and lymphoma specialist teams, Dr. Cashen cares for patients diagnosed with leukemia and lymphoma through treatment and recovery. Dr. Cashen also has expertise in myelodysplastic syndromes and stem-cell transplantation.

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Associate Chief of Hematologic Malignancies, WashU Medicine

Board Certification

  • 2002: American Board of Internal Medicine, Internal Medicine
  • 2006: American Board of Internal Medicine, Medical Oncology

Training

  • 1999 - 2002: Resident, Internal Medicine, WashU Medicine, St. Louis, MO
  • 2003 - 2006: Fellow, Hematology-Oncology, WashU Medicine, St. Louis, MO

Education

  • 1999: MD, WashU Medicine, St. Louis, MO

Research & Selected Publications

Research Interest

I conduct and participate in clinical trials focused on novel therapies for hematologic malignancies.

Research Publications

Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report
Authors:

Chiang TL, Frater J, Cashen A

Journal & Year:

Leuk Res Rep | 2026

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Authors:

Abboud R, Schroeder MA, Rettig MP, one or more additional authors omitted Cashen AF, one or more additional authors omitted DiPersio JF

Journal & Year:

Blood | 2025

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response
Authors:

Jacoby MA, Duncavage ED, Khanna A, one or more additional authors omitted Cashen A, one or more additional authors omitted Walter MJ

Journal & Year:

Leukemia | 2025

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies
Authors:

Desai P, Lonial S, Cashen A, one or more additional authors omitted Blachly JS

Journal & Year:

Clin Cancer Res | 2024

Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation
Authors:

Foltz JA, Tran J, Wong P, one or more additional authors omitted Cashen AF, one or more additional authors omitted Fehniger TA

Journal & Year:

Sci Immunol | 2024

The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
Authors:

Cashen AF

Journal & Year:

Front Oncol | 2024